Last updated: September 9, 2026
GLPG1690, also known as ziritaxestat, is an oral autotaxin inhibitor developed by Galapagos NV for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its development ended in 2021 after the Phase 3 ISABELA 1 and ISABELA 2 trials failed to show a favorable benefit-risk profile. GLPG1690 has no FDA approval, no Orange Book listing, no commercial sales, and no credible near-term market launch scenario.[1][2]
What is the current development status of GLPG1690?
GLPG1690 is a discontinued clinical-stage drug candidate. Galapagos and Gilead Sciences stopped the ISABELA Phase 3 program in February 2021 following a recommendation from the independent data monitoring committee. The committee found that the trials were unlikely to meet their efficacy objectives. The decision was based on lack of efficacy rather than a newly identified safety issue.[1]
| Development item |
Status |
| Active ingredient |
Ziritaxestat, GLPG1690 |
| Mechanism |
Autotaxin inhibition |
| Lead indication |
Idiopathic pulmonary fibrosis |
| Other investigated indications |
Systemic sclerosis and fibrotic diseases |
| Phase 2 IPF study |
FLORA completed |
| Phase 3 IPF studies |
ISABELA 1 and ISABELA 2 terminated |
| Regulatory approval |
None |
| FDA approval status |
Not approved |
| Commercial status |
No launch |
| Current revenue contribution |
None |
Galapagos subsequently removed GLPG1690 from its active development portfolio. The candidate is not an ongoing late-stage asset and has no current clinical development path disclosed by Galapagos.[1][3]
Why was the ISABELA Phase 3 program stopped?
The ISABELA program was stopped because interim efficacy results did not support continued development. The trials evaluated GLPG1690 in patients with IPF, a progressive lung disease characterized by declining pulmonary function and lung scarring.
The primary efficacy framework focused on change in forced vital capacity, or FVC, over the treatment period. The earlier Phase 2 FLORA study had generated interest because GLPG1690 appeared to stabilize FVC relative to placebo. The Phase 3 program did not confirm that result at the required level of clinical benefit.[1][4]
The discontinuation eliminated the principal path to registration in IPF. Because the drug did not demonstrate sufficient efficacy in its lead indication, the asset lost the commercial rationale for continued investment in additional fibrotic indications.
What were the key GLPG1690 clinical trials?
FLORA Phase 2 trial
The FLORA study was a randomized Phase 2 trial in patients with IPF. It evaluated GLPG1690 against placebo and measured lung-function outcomes, including FVC. Galapagos reported encouraging biomarker and lung-function findings, which supported advancement into Phase 3.[4]
The FLORA results did not establish approval-level evidence. The later ISABELA results were therefore critical to confirming whether the observed Phase 2 signal was reproducible in a larger patient population.
ISABELA 1 and ISABELA 2 Phase 3 trials
ISABELA 1 and ISABELA 2 were global Phase 3 studies designed to evaluate GLPG1690 in IPF. The program included patients receiving background treatment and was intended to support regulatory submissions if the efficacy endpoints were achieved.
The trials were terminated before completion after the data monitoring committee concluded that the studies were unlikely to demonstrate the required benefit. Galapagos and Gilead did not proceed with a marketing application for GLPG1690.[1][2]
NOVESA and other fibrotic-disease studies
GLPG1690 was also evaluated in systemic sclerosis and related fibrotic disease settings. Those studies were exploratory and did not create a viable alternative registration pathway after the IPF failure. The commercial program remained dependent on demonstrating meaningful clinical benefit in fibrotic lung disease.
What is the FDA regulatory status of GLPG1690?
GLPG1690 has no FDA approval and has not received a U.S. marketing authorization. The drug is not listed as an approved product in Drugs@FDA and has no approved labeling, established FDA dosage regimen, or commercial prescription status.[5]
The candidate did not reach the stage of a New Drug Application approval. Its clinical discontinuation means that the following regulatory events did not occur:
- No FDA approval for IPF.
- No approved indication for systemic sclerosis.
- No commercial launch date.
- No postmarketing safety program.
- No FDA-recognized market exclusivity period attached to an approved product.
Clinical-trial registration does not create a right to approval. GLPG1690’s Phase 3 termination ended the immediate regulatory pathway.
What is the Orange Book status of GLPG1690?
GLPG1690 has no Orange Book listing because the FDA has not approved the drug. As a result, there are no listed patents against which a generic applicant could file a Paragraph IV certification.[6]
| Orange Book issue |
GLPG1690 position |
| Approved reference-listed drug |
No |
| Orange Book product listing |
No |
| Listed drug patent |
No |
| Paragraph IV challenge |
None |
| Generic approval pathway |
Not applicable |
| Authorized generic risk |
None |
A patent may exist independently of an Orange Book listing, but an unapproved compound cannot generate the standard Hatch-Waxman patent-certification dispute associated with an approved product.
What patents protect GLPG1690?
GLPG1690 was supported by Galapagos patent filings covering the active compound, pharmaceutical compositions, therapeutic use, and potentially related formulation or manufacturing subject matter. The practical value of that estate fell sharply when the lead clinical program failed.
The key business distinction is between patent duration and commercial enforceability. Even if composition-of-matter patents remained in force after the 2021 discontinuation, they did not protect an approved product or generate marketed-product revenue.
Patent-estate assessment
| Patent category |
Commercial relevance |
| Compound patents |
Potentially strong for blocking use of the specific molecule, subject to claim scope and validity |
| Salt or crystal-form patents |
Narrower protection; relevance depends on the final clinical formulation |
| Formulation patents |
Limited value without an approved or commercially viable dosage form |
| Method-of-use patents |
Low practical value after failure in the principal disease |
| Manufacturing patents |
Could restrict production methods, but generally did not create a launch barrier without demand |
| Orange Book-listed patents |
None |
| Generic litigation exposure |
None in the conventional Hatch-Waxman sense |
No public commercial forecast should treat GLPG1690’s patent estate as equivalent to an active marketed-product estate. Patent expiry dates, prosecution outcomes, and jurisdiction-specific claim scope would need to be assessed family by family. The discontinued clinical status is the controlling commercial fact.
When did GLPG1690 lose exclusivity potential?
GLPG1690 lost practical exclusivity potential when the Phase 3 program was terminated in February 2021. Patent exclusivity and regulatory exclusivity are separate concepts, but both depend on a product reaching a commercially usable stage.
The candidate never obtained:
- New chemical entity exclusivity.
- Orphan-drug exclusivity.
- Pediatric exclusivity.
- Qualified infectious-disease exclusivity.
- FDA approval-based data exclusivity.
- An Orange Book-linked patent term extension.
Any remaining patent term therefore had residual defensive or licensing value rather than an established product-market value.
Which companies are challenging GLPG1690?
No generic company or biosimilar company is publicly associated with a challenge to GLPG1690. The asset is a small-molecule drug candidate, so biosimilar competition is not applicable.
The principal competitive pressure came from other IPF therapies rather than Paragraph IV litigation. The relevant approved competitors included:
- Ofev, or nintedanib, marketed by Boehringer Ingelheim.
- Esbriet, or pirfenidone, marketed by Genentech/Roche in the United States.
These products had established regulatory status and commercial access when GLPG1690 was discontinued.[7][8]
How does GLPG1690 compare with approved IPF drugs?
| Drug |
Mechanism |
Regulatory status |
Commercial position |
| GLPG1690 |
Autotaxin inhibitor |
Development terminated |
No sales |
| Nintedanib |
Tyrosine kinase inhibitor |
FDA approved for IPF |
Established standard therapy |
| Pirfenidone |
Antifibrotic with multi-pathway activity |
FDA approved for IPF |
Established standard therapy |
GLPG1690 was differentiated by its autotaxin mechanism and oral administration. That differentiation was not sufficient to overcome the lack of Phase 3 efficacy. The candidate therefore did not reach the market with a clinically validated advantage in FVC decline, tolerability, dosing convenience, or treatment durability.
What was the commercial opportunity for GLPG1690?
Before the ISABELA failure, GLPG1690 had a potentially significant commercial opportunity because IPF is a chronic, progressive disease with limited treatment options and long-term therapy requirements. A successful product could have competed in a global antifibrotic market supported by recurring treatment revenue.
That opportunity was dependent on four conditions:
- Demonstration of statistically and clinically meaningful efficacy.
- A tolerable safety profile suitable for chronic use.
- Approval in the United States, Europe, and other major markets.
- Differentiation against nintedanib and pirfenidone.
The first condition was not met. The market projection consequently changed from a potential specialty-pharmaceutical launch to a zero-revenue base case.
GLPG1690 revenue projection
| Projection period |
Expected commercial outcome |
| Historical period before Phase 3 termination |
No product revenue; clinical investment only |
| 2021 onward |
No launch revenue |
| Near term |
Zero base-case revenue |
| Medium term |
Zero base-case revenue absent an undisclosed asset transaction or restart |
| Long term |
No supportable commercial forecast based on disclosed development status |
A probability-adjusted valuation model should assign no meaningful risk-adjusted sales value to GLPG1690 unless a third party restarts development with new clinical evidence. A licensing transaction could create an upfront or milestone payment, but no disclosed transaction establishes a current market forecast.
What manufacturing and intellectual-property barriers remain?
GLPG1690’s manufacturing barriers are secondary to its clinical failure. The compound’s synthesis, scale-up, impurity control, and oral formulation could require specialized process development, but those issues were not the reason the program ended.
Potential technical barriers include:
- Reproducible production of the active pharmaceutical ingredient.
- Control of impurities and polymorphic forms.
- Stable oral solid-dose formulation.
- Commercial-scale process validation.
- Transfer of manufacturing know-how from the original developer.
- Freedom-to-operate analysis for compound and process claims.
These barriers could matter if the asset were revived. They do not create a current market-entry barrier because no approved GLPG1690 product exists.
What litigation or licensing activity affects GLPG1690?
No major public patent litigation involving an approved GLPG1690 product is associated with the discontinued program. There is no established Paragraph IV case, generic settlement, authorized-generic agreement, or biosimilar settlement.
Galapagos and Gilead had a broad collaboration involving Galapagos’ discovery portfolio, including GLPG1690. The Phase 3 discontinuation materially reduced the value of the program within that relationship. The commercial relevance of the collaboration is now historical rather than an indicator of active GLPG1690 development.[1][3]
How strong is the GLPG1690 patent estate?
The patent estate was likely strongest during the period when the molecule was advancing through clinical development and had a credible path to approval. Its practical strength is now low to moderate as a standalone commercial asset.
The assessment is:
- Compound protection: potentially meaningful if enforceable claims remain.
- Clinical differentiation: weak after the Phase 3 efficacy failure.
- Regulatory exclusivity: none.
- Orange Book leverage: none.
- Licensing value: limited and dependent on a new development thesis.
- Manufacturing value: potentially transferable but not independently sufficient.
- Generic threat: irrelevant without approval.
Patent validity and remaining term could still influence an asset sale, research collaboration, or compound repurposing effort. They do not support a conventional branded-product forecast.
Key Takeaways
- GLPG1690, or ziritaxestat, is a discontinued oral autotaxin inhibitor.
- Galapagos and Gilead stopped the ISABELA 1 and ISABELA 2 Phase 3 trials in February 2021 for lack of expected efficacy.
- The drug has no FDA approval, Orange Book listing, approved indication, or commercial revenue.
- No Paragraph IV challenge, generic litigation, biosimilar risk, or settlement affects the asset.
- The remaining patent estate may have defensive or licensing value, but it does not support a marketed-product valuation.
- The base-case market projection is zero revenue.
- Any future value would depend on a disclosed acquisition, clinical restart, new indication, or new efficacy evidence.
FAQs
Is GLPG1690 still being developed for idiopathic pulmonary fibrosis?
No. The Phase 3 ISABELA program was terminated in 2021, and no active development pathway has been disclosed.
Did GLPG1690 receive FDA Breakthrough Therapy or Fast Track approval?
No. FDA development designations, if granted during development, did not result in approval. GLPG1690 has no FDA marketing authorization.
Can a generic company launch GLPG1690?
No commercial generic pathway exists because GLPG1690 was never approved as a reference-listed drug in the United States.
Is GLPG1690 a biologic or a small-molecule drug?
GLPG1690 is a small-molecule oral drug candidate. Biosimilar regulation therefore does not apply.
Could GLPG1690 be revived for another fibrotic disease?
A revival is technically possible but would require a new clinical and commercial rationale. The failed IPF Phase 3 program substantially reduces the probability-adjusted value of such a strategy.
References
- Galapagos NV. (2021). Galapagos and Gilead discontinue ISABELA Phase 3 trials of ziritaxestat in IPF.
- ClinicalTrials.gov. (n.d.). Study of GLPG1690 in participants with idiopathic pulmonary fibrosis: ISABELA 1 and ISABELA 2. U.S. National Library of Medicine.
- Galapagos NV. (2022). Annual report 2021.
- Maher, T. M., van der Aar, E. M., Van de Steen, O., Allamaseeha, S., Desrivot, J., Dupont, S., et al. (2019). Safety, tolerability, and efficacy of autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis: The FLORA trial. The Lancet Respiratory Medicine, 7(10), 839-849.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2014). FDA approves Ofev to treat idiopathic pulmonary fibrosis.
- U.S. Food and Drug Administration. (2014). FDA approves Esbriet to treat idiopathic pulmonary fibrosis.